Genmab A/S, the Danish biotechnology company focused on human antibody therapeutics, has appointed David Eatwell as its new chief financial officer. Mr. Eatwell previously held the same position as Catalent Pharma Solutions, Inc. He is replacing Bo Kruse who was chief financial officer from 2000 until recently.
Source:
Genmab press release, 2 June 2008
Copyright Evernow Publishing 2008